WS #10273
AbbVie reportedly in talks to buy a biotech for $10.9B for an experimental eczema drug, potentially moving ABBV and target.
AbbVie Biotech Acquisition Talks
AbbVie reportedly in talks to buy a biotech for $10.9B for an experimental eczema drug, potentially moving ABBV and target.